Beyond immune checkpoint blockade: emerging immunological strategies.

Area of Science:

• Immunology
• Oncology
• Drug Discovery

Background:

• Checkpoint inhibitors have revolutionized cancer immunotherapy, leading to numerous single-agent and combination therapies.
• Despite successes, many immunotherapies have failed clinically as monotherapies or in combination, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To review the history of immunotherapy and checkpoint blockade, focusing on clinical failures.
• To explore critical aspects of the tumor microenvironment (TME) beyond T cell co-receptors for developing new immuno-oncology therapeutics.
• To identify key factors for future successful cancer therapeutics.

Main Methods:

• Review of historical immunotherapy and checkpoint blockade data.
• Analysis of clinical trial outcomes, particularly failures.
• Exploration of tumor microenvironment (TME) complexities and immune cell interactions.

Main Results:

• Numerous immunotherapies have faced clinical translation challenges.
• The tumor microenvironment (TME) presents multifaceted targets beyond T cell co-stimulation.
• Key therapeutic avenues include enhancing T cell function and modulating myeloid cell activity within the TME.

Conclusions:

• Future immuno-oncology therapeutics must address T cell dysfunction and homing within the TME.
• Re-engineering mononuclear phagocyte function is crucial for inflammatory remodeling in the TME.
• Developing effective anticancer drugs requires a comprehensive understanding of complex tumor cell-immune cell networks.